Skip to main content
SpringerLink
Log in

Why Neurotoxin Treatment is Generally Safe? What is the Long-Term Efficacy

  • Chapter
  • First Online:
Botulinum Toxin Treatment

  • 812 Accesses

Abstract

Botulinum neurotoxins (BoNTs) are now used widely in clinical medicine for treatment of diverse medical conditions. The FDA approved indications include, chronic migraine, spasticity (stiff muscles with high muscle tone), bladder dysfunction, cosmetic use, drooling and excessive perspiration, correction of squint (strabismus) and abnormal movements (dystonias). This chapter provides information on the safety and long-term use of botulinum toxin treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 59.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gracies J-M, Esquenazi A. Allison Brashear and others. Efficacy and safety of abobotulinumtoxinA in spastic lower limb Randomized trial and extension. Neurology. 2017;89:2245–53.

    Article  CAS  Google Scholar 

  2. Marciniak C, McAllister P, Walker H, other co-workers. Efficacy and safety of AbobotulinumtoxinA (Dysport) for the treatment of hemiparesis in adults with upper limb spasticity previously treated with botulinum toxin: sub-analysis from a phase 3 randomized controlled trial. PM&R. 2017;9:1181–90.

    Article  Google Scholar 

  3. Gracies JM, Brashear A, Jech R, co-workers. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomized controlled trial. Lancet Neurol. 2015;14:992–1001.

    Article  CAS  Google Scholar 

  4. Elovic EP, Munin MC, Kaňovský P, co-workers. Randomized, placebo-controlled trial of incobotulinumtoxina for upper-limb post-stroke. spasticity. Muscle Nerve. 2016;53:415–21.

    Article  CAS  Google Scholar 

  5. Pittock SJ, Moore AP, Hardiman O, co-workers. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis. 2003;15:289–300.

    Article  CAS  Google Scholar 

  6. Dunne JW, Gracies JM, Hayes M, co-workers. A prospective, multicentre, randomized, double-blind, placebo-controlled trial of onabotulinumtoxinA to treat plantarflexor/invertor overactivity after stroke. Clin Rehabil. 2012;26:787–97.

    Article  Google Scholar 

  7. Wein T, Esquenazi A, Jost WH and colleagues. OnabotulinumtoxinA for the Treatment of Poststroke Distal Lower Limb Spasticity: A Randomized Trial. PM R. 2018 Jan 9. pii: S1934–1482(17)30072–2. doi: https://doi.org/10.1016/j.pmrj.2017.12.006. [Epub ahead of print].

    Article  Google Scholar 

  8. Dressler D, Saberi FA, Kollewe K, Schrader C. Safety aspects of incobotulinumtoxinA high-dose therapy. J Neural Transm (Vienna). 2015;122(2):327–33.

    Article  CAS  Google Scholar 

  9. Wissel J, Bensmail D, Ferreira JJ, et al. Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: the TOWER study. Neurology. 2017;88:1321–8.

    Article  CAS  Google Scholar 

  10. Kolaski K, Coman A. Botulinum toxin for treatment of spasticity in cerebral palsy. In: Botulinum toxin treatment in clinical medicine – A disease oriented approach (Jabbari B, Editor): Springer Publishing; 2018. p. 81–108.

    Google Scholar 

  11. Ramirez-Castaneda J, Jankovic J. Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon. 2014;90:344–8.

    Article  CAS  Google Scholar 

  12. Misra VP, Colosimo C, Charles D. INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin. Neurol. 2018;265:402–9.

    Article  CAS  Google Scholar 

  13. Jog M, Wein T, Bhogal M. Real-world, long-term quality of life following therapeutic OnabotulinumtoxinA treatment. Can J Neurol Sci. 2016;43:687–96.

    Article  Google Scholar 

  14. Santamato A, Panza F, Intiso D, et al. Long-term safety of repeated high doses of incobotulinumtoxinA injections for the treatment of upper and lower limb spasticity after stroke. Neurol Sci. 2017;378:182–6.

    Article  CAS  Google Scholar 

  15. Kennelly M, Dmochowski R, Schulte-Baukloh H, et al. Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: final results of a long-term extension study. Neurourol Urodyn. 2017;36:368–375.24.

    Article  CAS  Google Scholar 

  16. Ababneh OH, Cetinkaya A, Kulwin DR. Long-term efficacy and safety of botulinum toxin a injections to treat blepharospasm and hemifacial spasm. Clin Exp Ophthalmol. 2014;42:254–61.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Emeritus Professor of Neurology, Yale University School of Medicine, New Haven, CT, USA

    Bahman Jabbari

Authors
  1. Bahman Jabbari
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Jabbari, B. (2018). Why Neurotoxin Treatment is Generally Safe? What is the Long-Term Efficacy. In: Botulinum Toxin Treatment . Springer, Cham. https://doi.org/10.1007/978-3-319-99945-6_15

Download citation

Publish with us

Policies and ethics

Search

Navigation